Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | DRD1 | P21728 | 5/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.47 |
| ▸ | DRD5 | P21918 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21759481 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL38666628 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL27321548 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL20324860 | 0.98 | GNAO1 (0.58) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL11929529 | 0.92 | GNAI3 (0.50) | GNAO1GNAI3GNAI1SIGMAR1HTR1A | |
| SCHEMBL11929534 | 0.92 | GNAI3 (0.50) | GNAO1GNAI3GNAI1SIGMAR1HTR1A | |
| SCHEMBL19275197 | 0.88 | GNAO1 (0.71) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL21024538 | 0.88 | GNAO1 (0.71) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL25963757 | 0.88 | GNAO1 (0.71) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL25834668 | 0.85 | GUSB (0.59) | GNAO1GNAI3GNAI1BCHEGUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | GNAO1 2683/4885GNAI3 2310/4885GNAI1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.